“The ability for generic and biosimilar manufacturers to procompetitively settle with brand-name drug manufacturers creates ...

Amgen’s biosimilar called Amjevita could provide cost savings to countless patients. Amjevita could generate $900 million in annual revenue for the drugmaker. The stock is a no-brainer buy for ...

All of this oversight momentum is evidence that the PBM Monopoly actively denies patients access to lower-cost, safe, and effective drugs — including biosimilars. This is unacceptable.